Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk? Suzanne B. CoopeyKinyas KartalKevin S. Hughes Review 21 January 2019 Pages: 1 - 4
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea Hope S. RugoJack A. Di PalmaLinda Bosserman Review Open access 22 January 2019 Pages: 5 - 15
Tamoxifen and pregnancy: an absolute contraindication? T. N. SchuurmanP. O. WitteveenC. A. R. Lok Review 01 February 2019 Pages: 17 - 25
The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer Rokaya El-AnsariMadeleine L. CrazeAndrew R. Green Preclinical Study 22 January 2019 Pages: 27 - 38
S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells Elena StrekalovaDmitry MalinVincent L. Cryns Preclinical study 02 February 2019 Pages: 39 - 50
Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases Zhi-Hua LiuKun WangFang-Ping Xu Preclinical study 02 February 2019 Pages: 51 - 57
An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network Min SunDi WuDong Huang Preclinical study 04 February 2019 Pages: 59 - 75
ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness Yin LiuPuspa R. PandeyKounosuke Watabe Preclinical study 06 February 2019 Pages: 77 - 90
Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer Yujia LanErjie ZhaoShujun Cheng Preclinical study 09 February 2019 Pages: 91 - 104
Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers Constantinos SavvaKaren De SouzaSrinivasan Madhusudan Preclinical study Open access 12 February 2019 Pages: 105 - 115
Prognostic effects of abnormal DNA damage response protein expression in breast cancer Koung Jin SuhHan Suk RyuSeock-Ah Im Clinical trial 22 January 2019 Pages: 117 - 127
Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer Nicola J. CampMichael J. MadsenPhilip S. Bernard Clinical trial Open access 23 January 2019 Pages: 129 - 139
Differences between screen-detected and interval breast cancers among BRCA mutation carriers Melissa PilewskieEmily C. ZaborMaxine S. Jochelson Clinical Trial 23 January 2019 Pages: 141 - 148
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES Zsolt SzijgyartoKoen D. FlachR. Charles Coombes Clinical trial Open access 24 January 2019 Pages: 149 - 163
Microchipping the breast: an effective new technology for localizing non-palpable breast lesions for surgery Maggie L. DiNomeAmy M. KusskeAnne C. Hoyt Clinical trial 28 January 2019 Pages: 165 - 170
The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial Shakiba FatehiRaziyeh MaasoumiSeyed Mohammad Mirrezaie Clinical trial 30 January 2019 Pages: 171 - 179
Factors influencing the use of extended adjuvant endocrine therapy Kunal C. KadakiaKelley M. KidwellN. Lynn Henry Clinical trial 31 January 2019 Pages: 181 - 189
Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial M. B. LigabueI. CampaniniA. Merlo Clinical trial 02 February 2019 Pages: 191 - 201
Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort Jiwoong JungWonshik HanYoung Up Cho Clinical trial 04 February 2019 Pages: 203 - 215
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer Ulrich BickChristoph Engelthe German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) Clinical trial 06 February 2019 Pages: 217 - 228
Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk Anna WeissSamantha GrossmithTari A. King Epidemiology 21 January 2019 Pages: 229 - 237
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction Yasin HussainEsther DrillAnthony F. Yu Epidemiology 05 February 2019 Pages: 239 - 246
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women Tess O’MearaAnton SafonovLajos Pusztai Epidemiology 06 February 2019 Pages: 247 - 259
HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment Kadri Altundag Letter to the Editor 01 February 2019 Pages: 261 - 261
Change in study randomization allocation needs to be included in statistical analysis: comment on ‘Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study’ Stephanie L. DickinsonLilian Golzarri-ArroyoDavid B. Allison Letter to the Editor 05 February 2019 Pages: 263 - 264
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial Ulrike NitzOleg GluzNadia Harbeck Correction Open access 10 January 2019 Pages: 265 - 266
